Aims of Journal of the International Child Neurology Association
Journal of the International Child Neurology Association (JICNA) is the official journal of the International Child Neurology Association publishes a variety articles (original research papers, reviews, commentaries and case reports concerning all aspects of child neurology and neuroscience. In particular, this journal aims to support authors with editing. Initially the journal will publish in English, but we plan to publish in other languages.
Why publish your article in JICNA?
All articles published by JICNA are made freely and permanently accessible online immediately upon publication, without subscription charges or embargo period. The articles are available to a wide, global audience.
Papers are published free
Although Open Access publishing has some expenses, initially there will be no charges to publish in JICNA, since ICNA has provided start up fees. This policy may be reviewed in the future.
JICNA aims to publish the papers on line as soon as they have been accepted and copy edited. The papers are submitted online, with electronic peer review which can be tracked and all articles are published with their final citation immediately upon acceptance. Thereafter the articles will be published in a web form and as a formatted PDF.
Publishing video and colour figures
Publication online allows videos and colour figures and pictures to be published without any additional cost.
Following publication in JICNA, the full-text of each article is deposited immediately and permanently in PubMed Central the digital archive of electronic publications. We plan to apply to Directory of Open Access Journals and National Library of Medicine to have the journal recognised in PubMed Central.
Articles published in JICNA are included in article alertsto ICNA members on publication
Publication and peer review process
All articles submitted to JICNA, articles will be peer reviewed by at least two reviewers, usually members of the Editorial Board or people with specific expertise in the subject matter of the paper. Articles should not be longer than 5000 words, but authors are encouraged to be more concise (usually about 3000 words) to encourage readership. The papers may be significantly edited to improve the English.
Statistical reviewers are used where required. In addition, advice on whether the article is of sufficient significance for publication in JICNA will generally be obtained from a member of the Editorial Board or a researcher of equivalent standing. Reviewers are asked to declare any competing interests and agree to open peer review. This includes: the authors receive the signed report and, if the manuscript is published, the same report is available to the readers. The pre-publication history (the dates of the initial submission, reviews and revisions) will be posted on the web with the published article. In cases where there is strong disagreement either among peer reviewers or between the authors and peer reviewers, advice is sought from a member of the journal's Editorial Board. Appeals should be directed to the Editor.
Authors will be able to check the progress of their manuscript through the submission system at any time by logging into the a personalized section of the JICNA website
JICNA offers a fast publication schedule even while maintaining rigorous peer review. Articles will be published with their final citation after acceptance, in both fully browsable html, and as a formatted PDF; the article will then be available at JICNA online
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.
All articles published in JICNA are copyedited before publication of the final version.
Articles published in JICNA are published immediately on acceptance in the form of a provisional PDF. Copyedited and fully formatted PDF and full-text (HTML) versions will be made available shortly thereafter.
Edited versions will be sent by email and corrections should be returned within two working days. Please provide a typed list of corrections clearly indicating where the corrections should be made and please send this list by email.
The editing is designed only to correct such things as misused words, spelling errors, missing references or incomplete citation information.
No printed reprints are available, since this is an e-journal
No manuscript or substantial parts of it, must not be under consideration by another journal. In general, the manuscript should not have already been published in any journal or other citable form. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights, or the rights of a third party.
Correspondence concerning articles published in JICNA is encouraged. A 'post a comment' feature is available on all articles published by JICNA. Comments will be moderated by the editorial office (see our Comment policy for further information) and linked to the full-text version of the article, if suitable.
We endorse the World Association of Medical Editors (WAME) Policy Statement on Geopolitical Intrusion on Editorial Decisions.
Submission of a manuscript to JICNA implies that all authors have read and agreed to its content, and that any experimental research that is reported in the manuscript has been performed with the approval of an appropriate ethics committee. Research carried out on humans must be in compliance with the Helsinki Declaration, and any experimental research on animals must follow internationally recognized guidelines. A statement to this effect must appear in the Methods section of the manuscript, including the name of the body which gave approval, with a reference number where appropriate. Informed consent must also be documented. Manuscripts may be rejected if the editorial office considers that the research has not been carried out within an ethical framework.
For all articles that include information or clinical photographs relating to individual patients, written and signed consent from each patient to publish must also be made available.
ICNA has a legal responsibility to ensure that its journal does not publish material that infringes copyright, or that includes libellous or defamatory content. If the manuscript is perceived to contain potentially libellous content, the authors will be approached to ensure an appropriate outcome is reached.
The involvement of scientific (medical) writers or anyone else who assisted with the preparation of the manuscript content should be acknowledged, along with their source of funding, as described in the European Medical Writers Association (EMWA) guidelines on the role of medical writers in developing peer-reviewed publications. If medical writers are not listed among the authors, their role should be acknowledged explicitly.
JICNA recommend authors refer to the EQUATOR network website for further information on the available reporting guidelines for health research, and the MIBBI Portal for prescriptive checklists for reporting biological and biomedical research where applicable. Authors are requested to make use of these when drafting their manuscript and peer reviewers will also be asked to refer to these checklists when evaluating these studies.
Checklists are available for a number of study designs include:
For authors of systematic reviews, an additional file, linked from the Methods section, should reproduce all details concerning the search strategy. For mutation nomenclature please use the guidelines suggested by the Human Genome Variation Society, and the recommended gene name by consulting the appropriate genetic nomenclature database, e.g., HUGO for human genes, and the International Committee on Standardized Genetic Nomenclature for Mice.
We encourage the use of standardized terms for human phenotypes, such as those proposed by the Elements of Morphology working group (see:http://research.nhgri.nih.gov/morphology/index.cgi).
Authors from pharmaceutical companies, or other commercial organizations that sponsor clinical trials, should adhere to the Good Publication Practice guidelines for pharmaceutical companies, which are designed to ensure that publications are produced in a responsible and ethical manner. The guidelines also apply to any companies or individuals that work on industry-sponsored publications, such as freelance writers, contract research organizations and communications companies.
JICNA also supports initiatives to improve the performance and reporting of trials, which includes prospective registering and numbering of clinical trials. The International Committee of Medical Journal Editors (ICMJE) has implemented the World Health Organization (WHO) definition of clinical trials which states that a clinical trial is any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes. This definition includes phase I to Phase IV trials.
Authors of protocols or reports of such clinical trials, where the primary purpose of the research is to understand the causes, development and effects of disease or to improve preventative, diagnostic or therapeutic interventions, must register their trials prior to submission in a suitable publicly available registry. In addition to accepting registration in any of the five existing registries (http://www.icmje.org/faq.html), the ICMJE will accept registration of clinical trials in any of the primary registers that participate in the WHO International Clinical Trials Registry Platform.
The trial registration number should be included as the last line of the manuscript abstract
Submission of a manuscript to JICNA implies that readily reproducible materials described in the manuscript, including all relevant raw data, will be freely available to any scientist wishing to use them for non-commercial purposes. Nucleic acid sequences, protein sequences, and atomic coordinates should be deposited in an appropriate database in time for the accession number to be included in the published article. Any 'in press' articles cited within the references and necessary for the reviewers' assessment of the manuscript should be made available if requested by the editorial office.
Nucleotide sequences can be deposited with the DNA Data Bank of Japan (DDBJ), European Molecular Biology Laboratory (EMBL/EBI) Nucleotide Sequence Database, or GenBank (National Center for Biotechnology Information).
The accession numbers of any nucleic acid sequences, protein sequences or atomic coordinates cited in the manuscript should be provided, in square brackets with the corresponding database name; for example, [EMBL:AB026295, EMBL:AC137000, DDBJ:AE000812, GenBank:U49845, PDB:1BFM, Swiss-Prot:Q96KQ7, PIR:S66116].
The databases for which we can provide direct links are: EMBL Nucleotide Sequence Database (EMBL), DNA Data Bank of Japan (DDBJ), GenBank at the NCBI (GenBank), Protein Data Bank (PDB), Protein Information Resource (PIR) and the Swiss-Prot Protein Database (Swiss-Prot).
Mass spectrometry data should be supplied in the mzML format recommended by the HUPO Protein Standards Initiative Mass Spectrometry Standards Working Group guidelines (http://www.psidev.info/index.php?q=node/80). We also recommend that the data is deposited in the ProteomeExchange (http://proteomexchange.org/) through the PRIDE website (http://www.ebi.ac.uk/pride/), and protein interaction data can be submitted to members of the IMEx consortium (http://www.imexconsortium.org/submit-your-data).
Protein structures can be deposited with one of the members of the Worldwide Protein Data Bank. Nucleic Acids structures can be deposited with the Nucleic Acid Database at Rutgers. Crystal structures of organic compounds can be deposited with the Cambridge Crystallographic Data Centre.
Chemical structures and assays
Functional genomics data (such as microarray, RNA-seq or ChIP-seq data)
Where appropriate, authors should adhere to the standards proposed by the Functional Genomics Data Society and must deposit microarray data in MIAME-compliant format in one of the public repositories, such as ArrayExpress or Gene Expression Omnibus (GEO). Deposition of high-throughput functional genomics sequencing data (such as RNA-Seq or ChIP-Seq data) with ArrayExpress or GEO in compliance with MINSEQE is also required
Authors who wish to appeal a rejection or make a complaint should, in the first instance, contact the Editor who will provide details of the journal's complaints procedure.
JICNA requires authors to declare any competing financial or other interest in relation to their work. All competing interests that are declared will be listed at the end of published articles. Where an author gives no competing interests, the listing will read 'The author(s) declare that they have no competing interests'.
Plagiarism of other peoples work or the authors own work is not acceptable. The editorial staff may use plagiarism software to check the authenticity of the paper.
Articles in JICNA will be given a unique article number. Thus articles should be citated as:
Authors: Title. JICNA [year] [volume]:[article number].
e.g. Charles R Newton, Hameed Biju. Why another journal on Child Neurology? JICNA 2012 10:1.
refers to article 1 published in 2012 vol 10
Authors of articles published in JICNA retain the copyright of their articles and are free to reproduce and disseminate their work according to the JICNA copyright and license agreement.